PLIANT THERAPEUTICS, INC.
PLRXNasdaq
$1.15
↑ +3.6%Jul 17 close · end-of-day
Price
1Y↓ -14.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$71.1M
Enterprise Value
-$99.8M
P/E
—
P/S
—
P/B
0.4
EV/EBITDA
—
PEG
—
FCF Yield
-139.0%
Dividend Yield
0.0%
Revenue (TTM)
—
Net Income (TTM)
$185.4M
Free Cash Flow (TTM)
-$98.8M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
112.3%
ROIC
—
Debt / Equity
0.0
Net Cash
$170.9M
Return 1Y
-19.0%
Company profile
Pliant Therapeutics, Inc. discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins.
- CEO
- Bernard Coulie
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 90
- Headquarters
- California
- Website
- pliantrx.com
Management & directors
- Cheung LilyChief Human Resource Officer
- Coulie BernardPresident and CEO
- Cummings Keith LamontChief Financial Officer
- Kuo MinnieChief Operating Officer
Roles derived from SEC Form 4 filings.
Earnings
PLRX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.32↓ -65.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $41.8M | $7.6M | $9.7M | $1.6M | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$41.6M | -$97.5M | -$127.2M | -$184.1M | -$228.4M | -$156.4M |
| Net income | -$41.5M | -$97.3M | -$123.3M | $161.3M | $210.3M | $149.3M |
| Diluted EPS | -$1.95 | -$2.71 | -$2.94 | -$2.75 | -$3.47 | -$2.43 |
| Operating cash flow | -$37.3M | -$75.4M | -$94.6M | -$116.4M | -$155.5M | -$128.3M |
| Free cash flow | -$38.8M | -$77.4M | -$96.4M | -$117.3M | -$159.4M | -$128.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -99.6% | -1288.1% | -1313.4% | -11654.7% | — | — |
| Net margin | -99.3% | -1284.5% | -1273.3% | 10208.9% | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$60.6M | -$62.0M | -$53.3M | -$58.9M | -$45.6M | -$28.3M | -$23.6M | -$21.8M |
| Net income | -$55.9M | -$57.8M | $370.9M | -$56.2M | -$43.3M | -$26.3M | $275.1M | -$20.0M |
| Diluted EPS | -$0.92 | -$0.95 | -$0.82 | -$0.92 | -$0.71 | -$0.43 | -$0.37 | -$0.32 |
| Operating cash flow | -$45.3M | -$32.3M | -$47.7M | -$48.9M | -$40.6M | -$21.1M | -$17.8M | -$19.2M |
| Free cash flow | -$46.5M | -$33.2M | -$47.9M | -$49.1M | -$40.7M | -$21.1M | -$17.8M | -$19.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-01-20 | Coulie Bernard· President and CEO | Sale | 89,375 | $1.28 | $114,400.00 | filing |
| 2026-01-20 | Cummings Keith Lamont· Chief Financial Officer | Sale | 24,002 | $1.28 | $30,722.56 | filing |
| 2026-01-20 | Cheung Lily· Chief Human Resource Officer | Sale | 7,534 | $1.28 | $9,643.52 | filing |
| 2026-01-20 | Kuo Minnie· Chief Operating Officer | Sale | 6,917 | $1.28 | $8,853.76 | filing |
Latest 4 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.